Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

• Published in: Hepatology international Vol. 14; no. 6; pp. 985 - 996
• Main Authors: Li, Xiaoke, Zhou, Daqiao, Chi, Xiaoling, Li, Qin, Wang, Li, Lu, Bingjiu, Mao, Dewen, Wu, Qikai, Wang, Xianbo, Zhang, Mingxiang, Xue, Jingdong, Li, Yong, Lu, Wei, Guo, Jianchun, Jiang, Feng, Zhang, Xinwei, Li, Zhiguo, Yang, Xianzhao, Guo, Hui, Gan, Danan, He, Liyun, Luo, Lin, Zhang, Ludan, Du, Hongbo, Ye, Yong’an
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.12.2020; Springer Nature B.V
• Subjects: Adverse events; Antigens; Antiviral Agents - therapeutic use; Antiviral drugs; Clinical trials; Colorectal Surgery; Deoxyribonucleic acid; DNA; DNA, Viral; Drug Combinations; Drugs, Chinese Herbal - therapeutic use; Enzymes; Granular materials; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis; Hepatitis B; Hepatitis B e antigen; Hepatitis B e Antigens; Hepatitis B surface antigen; Hepatitis B virus - genetics; Hepatitis B, Chronic - drug therapy; Hepatology; Herbal medicine; Humans; Liver; Medicine; Medicine & Public Health; Nucleoside analogs; Original Article; Placebos; Statistical analysis; Surgery; Therapy; Traditional Chinese medicine; Treatment Outcome; Traditional Chinese medicine; Tiao-gan-yi-pi granule; Chronic hepatitis B; Tiao-gan-jian-pi-jie-du granule
• ISSN: 1936-0533; 1936-0541; 1936-0541
• DOI: 10.1007/s12072-020-10097-z

Background and aim Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients. Methods 596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108. Results The combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9–43.2%) in the experiment group and 27.21% (95% CI 22.0–32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4–12.3%, p  = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week. Conclusion Combining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile. Clinical trial number ChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).